US Bancorp DE Sells 8,482 Shares of STERIS plc $STE

Key Points

• US Bancorp DE has reduced its stake in STERIS plc by 35.4%, selling 8,482 shares, and now holds 15,502 shares valued at approximately $3.72 million.
• Institutional investors now own 94.69% of STERIS's stock, with notable increases from firms like Geneos Wealth Management (up 416.0%) and Grove Bank & Trust (up 4,733.3%) during the first quarter.
• STERIS recently boosted its quarterly dividend to $0.63 per share, reflecting a 10.53% increase from the previous dividend of $0.57.

US Bancorp DE decreased its position in STERIS plc (NYSE:STE - Free Report) by 35.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,502 shares of the medical equipment provider's stock after selling 8,482 shares during the quarter. US Bancorp DE's holdings in STERIS were worth $3,724,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Geneos Wealth Management Inc. raised its position in shares of STERIS by 416.0% in the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider's stock valued at $29,000 after purchasing an additional 104 shares during the period. Grove Bank & Trust raised its position in shares of STERIS by 4,733.3% in the first quarter. Grove Bank & Trust now owns 145 shares of the medical equipment provider's stock valued at $33,000 after purchasing an additional 142 shares during the period. Zions Bancorporation National Association UT bought a new position in shares of STERIS in the first quarter valued at approximately $37,000. ORG Wealth Partners LLC bought a new position in shares of STERIS in the first quarter valued at approximately $43,000. Finally, Golden State Wealth Management LLC raised its position in shares of STERIS by 503.0% in the first quarter. Golden State Wealth Management LLC now owns 199 shares of the medical equipment provider's stock valued at $45,000 after purchasing an additional 166 shares during the period. Institutional investors own 94.69% of the company's stock.

Insider Transactions at STERIS

In other news, VP Renato Tamaro sold 3,204 shares of the business's stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $249.24, for a total value of $798,564.96. Following the sale, the vice president owned 7,221 shares in the company, valued at approximately $1,799,762.04. The trade was a 30.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Cynthia L. Feldmann sold 3,495 shares of the business's stock in a transaction on Monday, August 11th. The shares were sold at an average price of $241.56, for a total transaction of $844,252.20. Following the completion of the sale, the director owned 705 shares in the company, valued at $170,299.80. This represents a 83.21% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,868 shares of company stock worth $4,585,389. 1.07% of the stock is currently owned by company insiders.

STERIS Trading Down 0.1%

Shares of STERIS stock opened at $235.65 on Tuesday. The firm has a market capitalization of $23.21 billion, a PE ratio of 36.09 and a beta of 1.01. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.22 and a quick ratio of 1.53. The company's fifty day moving average price is $244.47 and its two-hundred day moving average price is $236.06. STERIS plc has a 52-week low of $200.98 and a 52-week high of $253.00.

STERIS (NYSE:STE - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $2.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.32 by $0.02. The firm had revenue of $1.40 billion for the quarter, compared to analyst estimates of $1.36 billion. STERIS had a net margin of 11.61% and a return on equity of 14.17%. The business's revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.03 EPS. On average, analysts expect that STERIS plc will post 9.08 EPS for the current year.

STERIS Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, September 26th. Shareholders of record on Thursday, September 4th were issued a $0.63 dividend. This is a boost from STERIS's previous quarterly dividend of $0.57. The ex-dividend date of this dividend was Thursday, September 4th. This represents a $2.52 annualized dividend and a yield of 1.1%. STERIS's payout ratio is presently 38.59%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on STE shares. Morgan Stanley boosted their target price on shares of STERIS from $276.00 to $295.00 and gave the stock an "overweight" rating in a research report on Friday, August 8th. Weiss Ratings reaffirmed a "buy (b-)" rating on shares of STERIS in a research report on Saturday, September 27th. KeyCorp boosted their target price on shares of STERIS from $277.00 to $288.00 and gave the stock an "overweight" rating in a research report on Tuesday, July 22nd. Finally, Wall Street Zen raised shares of STERIS from a "buy" rating to a "strong-buy" rating in a research report on Sunday, September 14th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $273.50.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.